Related Experiment Video
Updated: Aug 27, 2026
Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model
Published on: July 2, 2016
A modified SCID mouse model of HIV infection with utility for testing anti-HIV therapies
Seth H Pincus1, Hua Fang, Royce A Wilkinson
1Department of Microbiology, Montana State University, Bozeman, MT 59717, USA. spincus@chnola-research.org
Abstract:
Using human tumor cells we have developed a mouse model of active HIV infection that may be used for testing antiviral agents, although it does not reflect the pathogenesis of human infection. Irradiated SCID/NOD mice are injected with a tumor of human CD4+ lymphoma cells susceptible to infection and at a separate site, tumor cells persistently infected with either primary or T cell line-adapted strains of HIV. The spread of infection from the infected to the susceptible tumor is monitored as plasma p24 and the presence of HIV-infected cells in the spleen. We have used this model to examine the relative efficacy of neutralizing anti-HIV antibodies to halt the spread of infection. We have found that the tetrameric CD4-antibody fusion protein, CD4-IgG2, is highly effective compared to an anti-V3 loop antibody. This animal model, while not replicating the human disease, allows for the simultaneous testing of efficacy, toxicity, and pharmacokinetics of potential new antiviral therapies. The model can easily be powered to enable comparisons between different therapeutic agents and dosing regimens.
Insights
A new mouse model using human tumor cells allows testing of antiviral drugs for HIV infection. CD4-IgG2 antibody demonstrated high efficacy in halting infection spread in this model.
Area of Science:
- Immunology
- Virology
- Animal Models
Background:
- Developing effective antiviral therapies for Human Immunodeficiency Virus (HIV) requires robust preclinical models.
- Existing models may not fully capture the complexities of HIV pathogenesis or allow for comprehensive drug evaluation.
Purpose of the Study:
- To develop and validate a novel mouse model for assessing the efficacy of antiviral agents against active HIV infection.
- To evaluate the effectiveness of neutralizing anti-HIV antibodies in preventing viral spread within this model.
Main Methods:
- Human CD4+ lymphoma cells susceptible to HIV infection were xenografted into irradiated SCID/NOD mice.
- Tumor cells persistently infected with HIV were co-injected at a separate site.
- Infection spread was monitored via plasma p24 levels and HIV-infected cells in the spleen.
- The efficacy of CD4-IgG2 and an anti-V3 loop antibody was compared.
Main Results:
- The developed mouse model demonstrated active HIV infection and allowed monitoring of viral spread.
- The tetrameric CD4-IgG2 fusion protein showed significantly higher efficacy in halting HIV spread compared to an anti-V3 loop antibody.
- The model facilitates simultaneous assessment of antiviral efficacy, toxicity, and pharmacokinetics.
Conclusions:
- This xenograft mouse model provides a valuable platform for preclinical testing of novel antiviral therapies for HIV.
- CD4-IgG2 represents a highly effective therapeutic candidate for inhibiting HIV transmission.
- The model's adaptability allows for comparative analysis of various therapeutic agents and dosing strategies.
